Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on October 3, 2022, reporting events that occurred on September 30, 2022. The filing details a private placement offering and a concurrent extension of an existing financing agreement.
Key Financial Metrics and Transactions
- Capital Raised: The Company received gross proceeds of $7 million from the sale of 7,000 shares of Series A Preferred Stock to Rubric Capital Management LP.
- Use of Proceeds: Net proceeds are designated for working capital and general corporate purposes.
- Debt Extension: The maturity date of the Financing Agreement with Sixth Street Specialty Lending, Inc. and other lenders was extended to October 31, 2022.
- Equity Issuance: The Company issued 125,000 warrants (Lender Warrants) to lenders with an exercise price of $0.01 per share and an expiration date of September 30, 2032.
- Make-Whole Provision: Instead of issuing 263,666 shares of common stock, the Company agreed to a future cash make-whole payment to the investor based on the closing stock price prior to payment.
Material Changes Versus Prior Period
This filing represents a discrete event rather than a periodic financial update. Consequently, there are no comparative revenue, profit, or cash flow metrics provided in this document. The material change is the entry into a definitive subscription agreement and the extension of debt maturity, which alters the Company's capital structure and liquidity position relative to the prior period.
Guidance, Outlook, and Risks
- Management Commentary: Management intends to utilize the $7 million in proceeds to support working capital needs.
- Investor Rights: The investor was granted rights of first refusal on subsequent equity offerings while the Series A Preferred Stock remains outstanding.
- Regulatory Status: The securities were sold unregistered under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
- Contingencies: The make-whole payment obligation is contingent on the later of the Maturity Date of the Preferred Stock or the full repayment of the Financing Agreement.
Important Facts for Investor Verification
- Verify the specific terms of the Certificate of Designation for the Series A Preferred Stock to understand dividend rights and liquidation preferences.
- Confirm the status of the Financing Agreement with Sixth Street Specialty Lending, Inc., given the maturity extension to October 31, 2022.
- Review the calculation methodology for the make-whole payment obligation of 263,666 shares to assess potential future cash outflows.
- Check subsequent filings for the actual use of the $7 million proceeds and any further dilution from the exercise of the 125,000 Lender Warrants.